Research Tracker›Biomarker Atlas›Long COVID›Pro-inflammatory cytokines (composite)

Pro-inflammatory cytokines (composite) in Long COVID

In Long COVID (PASC, Post-Acute Sequelae of COVID-19), published studies report lower levels of Pro-inflammatory cytokines (composite), also described as IL-1β, IL-8, IFN-γ, etc., than in recovered individuals without persistent symptoms (at 6 months). The cited literature links this alteration to immune exhaustion pattern. The evidence summarised here comes from Kallaste et al. 2025 and reflects averages across cohorts rather than any single patient's result.

↓ ReducedInflammatory

Summary

Direction in Long COVID↓ Reduced — lower than in the comparison group
CategoryInflammatory
Also described asIL-1β, IL-8, IFN-γ, etc.
Compared againstR (at 6 months) (recovered individuals without persistent symptoms (at 6 months))
Associated symptomsImmune exhaustion pattern
Test typeBlood test (serum / plasma / whole blood)
SourceKallaste et al. 2025 — doi:10.3390/medicina61060996
Condition atlasLong COVID Biomarker Atlas

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term Changes in Neuroimmune Functioning Measured by Pro-Inflammatory Cytokines (4 registered trials use a matching outcome measure).

Clinical trials using Pro-inflammatory cytokines (composite) as an outcome

NCT06211062Recruiting
The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Outcome measure: The pro-inflammatory cytokines level e.g. IL-1, IL-6, and TNF-α
NCT01650636Completed
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
Outcome measure: Changes in Neuroimmune Functioning Measured by Pro-Inflammatory Cytokines
NCT06294756Completed
Sulfureous Water Therapy in Viral Respiratory Diseases
Outcome measure: To assess if H2S present in STW can interfere with concentration of inflammatory markers ( as IL1B, IL-6, ACE, S100B, GSS, Hs-CRP) typically alterated in long covid patients.
NCT05128292Completed
Effect of CoQ10 Plus Selenium Supplementation on Clinical Outcomes and Biochemical Markers in ME/CFS (CoSeME Study)
Outcome measure: Measurement of biomarkers of inflammatory immune response.

Interventions studied alongside this marker

Hypothesis-generating links from trial outcome usage and literature co-occurrence. Not treatment recommendations.

Related Inflammatory markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is Pro-inflammatory cytokines (composite) high or low in Long COVID?

Reduced. Studies summarised in the OSMF atlas report lower Pro-inflammatory cytokines (composite) in Long COVID than in recovered individuals without persistent symptoms (at 6 months). Source: Kallaste et al. 2025.

What symptoms is Pro-inflammatory cytokines (composite) associated with in Long COVID?

The cited literature associates this marker with Immune exhaustion pattern. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Pro-inflammatory cytokines (composite)?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Pro-inflammatory cytokines (composite) result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. Pro-inflammatory cytokines (composite) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). Pro-inflammatory cytokines (composite) in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved November 10, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/pro-inflammatory-cytokines-composite.html

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.